Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 6/20 | 0.40 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 5/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | FABP7 | O15540 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8847169 | 1.00 | PDPK1 (0.43) | PDPK1PPARGPPARACYP2D6SRC | |
| SCHEMBL5642476 | 0.98 | PDPK1 (0.44) | PDPK1PPARGPPARACYP2D6SRC | |
| SCHEMBL5640880 | 0.98 | PDPK1 (0.44) | PDPK1PPARGPPARACYP2D6SRC | |
| SCHEMBL893601 | 0.98 | PDPK1 (0.44) | PDPK1PPARGPPARACYP2D6SRC | |
| SCHEMBL7344512 | 0.85 | EPHX2 (0.41) | PPARGPPARALMNAEPHX2 | |
| SCHEMBL11825339 | 0.85 | EPHX1 (0.41) | PDPK1CYP2D6LMNAMAPK1FABP7 | |
| SCHEMBL527394 | 0.85 | PDPK1 (0.39) | PDPK1PPARGPPARALMNAFABP7 | |
| SCHEMBL7341580 | 0.83 | PNMT (0.51) | PPARGPPARA | |
| SCHEMBL8171416 | 0.82 | KMT2A (0.50) | LMNA | |
| SCHEMBL7344139 | 0.82 | MEN1 (0.48) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2803358-B1 | 10,10-Dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9637467-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9334262-B2 | Methods of treating soft tissue defects | ALLERGAN, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160096817-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9156810-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9005605-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8926963-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8900571-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8894992-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2803358-A1 | 10,10-Dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2014-11-19 | — | — | EP | disclosed |
| US-5824830-A | USEFUL AS HYDROGENATION CATALYSTS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1998-10-20 | — | — | US | disclosed |
| EP-0826694-A1 | Ruthenium-phosphine complex | Takasago International Corporation (JP) | 1998-03-04 | — | — | EP | disclosed |
| US-5654432-A | NAPHTHYLISOQUINOLINE ALKALOID ISOLATED FROM ANCISTROCLADUS SP. NOVUM VIA ORGANIC SOLVENT EXTRACTION, ACID-BASE PARTITIONING, CENTRIFUGAL PARTITION CHROMATOGRAPHY, AND HPLC USING AN AMINO-BONDED PHASE COLUMN; VIRICIDE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0519763-B1 | Cyclohexylbutyric acid derivatives and their use in the production of optically active cyclohexylnorstatine | TAKASAGO PERFUMERY CO LTD (JP) | 1997-02-05 | — | — | EP | disclosed |
| US-5502221-A | HYPOTENSIVE INTERMEDIATE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1996-03-26 | — | — | US | disclosed |
| US-5455251-A | Treatment of AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-10-03 | — | — | US | disclosed |
| US-5442105-A | Catalytic hydrogenation, epoxidation, reacting product with trialkylsilyl azide in the presence of a Lewis acid, hydrogenolysis | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1995-08-15 | — | — | US | disclosed |
| US-5409938-A | A plant extracts having a naphthyl-tetrahydroisoquinolines group; a new drug treating malarial, parasiticides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1994024108-A1 | MICHELLAMINES USEFUL AS ANTIVIRAL AGENTS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0519763-A2 | Cyclohexylbutyric acid derivatives and their use in the production of optically active cyclohexylnorstatine | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1992-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096817-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | SLC10A2, FABP2, LTB4R2 | PPARG 366/4885SRC 3943/4885PDPK1 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.